C
Incyte Corporation INCY
$105.98 $0.780.74% NASDAQ
Recommendation
Prev Close
$105.20
Volume
2,019,980
Avg Vol (90D)
1,947,378
Market Cap
$20.65B
Dividend & Yield
--
52-Week Range
$53.56 - $106.47
P/E (TTM)
17.63
EPS (TTM)
$5.97
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Can Incyte Deliver on 447% EPS Forecasts and Pipeline Hype?
8/29/2025 - MarketBeat
Prelude Therapeutics (PRLD): Evaluating Valuation After Incyte Deal and Strategic Pipeline Shift
11/8/2025 - Simply Wall St
Incyte (NASDAQ:INCY) EVP Sells $60,613.28 in Stock
11/7/2025 - MarketBeat
Incyte (NASDAQ:INCY) EVP Sells $60,613.28 in Stock
11/7/2025 - MarketBeat
Sound Shore Management Inc CT Decreases Position in Incyte Corporation $INCY
11/7/2025 - MarketBeat
1 Cash-Producing Stock Worth Your Attention and 2 Facing Headwinds
11/7/2025 - StockStory Articles
Incyte (NASDAQ:INCY) EVP Lee Heeson Sells 3,074 Shares
11/6/2025 - MarketBeat
Incyte's Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo ...
11/6/2025 - GuruFocus
Incytes Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema
11/6/2025 - Business Wire
Lee Heeson Sells 3,074 Shares of Incyte (NASDAQ:INCY) Stock
11/6/2025 - MarketBeat
incyte expands awards program skin condition ahead fda filing
11/6/2025 - FiercePharma
Incyte (INCY): Buy, Sell, or Hold Post Q3 Earnings?
11/6/2025 - StockStory Articles
Incyte (NASDAQ:INCY) Stock Price Expected to Rise, Piper Sandler Analyst Says
11/5/2025 - MarketBeat
Strs Ohio Sells 3,126 Shares of Incyte Corporation $INCY
11/5/2025 - MarketBeat
Why Prelude Therapeutics (PRLD) Is Up 14.3% After Incyte Backs $25M Private Placement - And What's Next
11/5/2025 - Simply Wall St
Natera (NTRA) Reports Earnings Tomorrow: What To Expect
11/5/2025 - StockStory Articles
Incyte (INCY) Receives Raised Price Target from Piper Sandler INCY Stock News
11/4/2025 - GuruFocus
Incyte (NASDAQ:INCY) Hits New 52-Week High After Analyst Upgrade
11/4/2025 - MarketBeat
Incyte (INCY) Secures $935M Deal with Prelude Therapeutics for JAK2 Inhibitor
11/4/2025 - GuruFocus
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
11/4/2025 - Zacks Investment Research
Incyte inks option agreement with Prelude for JH2 inhibitor program
11/4/2025 - Seeking Alpha - Healthcare
Prelude Therapeutics Signs Option Agreement with Incyte
11/4/2025 - TipRanks Financial Blog
Incyte price target raised to $102 from $82 at Piper Sandler
11/4/2025 - TipRanks Financial Blog
Incyte price target raised by $20 at Piper Sandler, here's why
11/4/2025 - The Fly
Incyte (NASDAQ:INCY) Upgraded by Guggenheim to Buy Rating
11/4/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$4.81B
EBITDA (TTM)
$1.36B
EBIT (TTM)
$1.26B
Net Income (TTM)
$1.19B
Balance Sheet
Total Assets (Q)
$6.33B
Total Debt (Q)
$41.27M
Total Liabilities (Q)
$1.68B
Book Value Per Share (Q)
$23.71
Cash Flow
Cash from Operations (TTM)
$1.25B
Cash from Investing (TTM)
-$86.66M
Cash from Financing (TTM)
-$16.31M
Net Change in Cash (TTM)
$1.15B
Filings
Filing Date
Tuesday, October 28, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 9 and 13 (est)
Price History
Loading...
Beta
0.73
7-Day Total Return
17.52%
30-Day Total Return
28.15%
60-Day Total Return
23.00%
90-Day Total Return
55.46%
Year to Date Total Return
52.42%
1-Year Total Return
28.71%
2-Year Total Return
93.68%
3-Year Total Return
39.63%
5-Year Total Return
30.39%
52-week Low
Apr 09, 2025 - $53.56
52-week High
Nov 05, 2025 - $106.47
Valuation
Market Cap
$20.65B - Large Cap
Enterprise Value
$17.76B
Price/Sales (TTM)
4.40
Price/Book (Q)
4.44
Dividends and Shares
Shares Outstanding
201.43
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.incyte.com
Phone Number
302 498 6700
Address
1801 Augustine Cut-Off
Wilmington, DE 19803
Country
United States
Year Founded
1991
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers... more
NASDAQ 11/07/2025 4:00PM Eastern Quotes delayed